Chuyue Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chuyue Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kanapin
Peter the Great St. Petersburg Polytechnic University
1 shared publication - Anastasia Samsonova
Peter the Great St. Petersburg Polytechnic University
1 shared publication Annalisa Nicastri
The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication- Claire Hutchings
Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
1 shared publication - Garret Rochford
Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Oxford, UK
1 shared publication - Nicholas Barrie La Thangue
Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (9) , 3677-3703
PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer
PRMT5 is expressed at high levels in many cancers, where it regulates diverse cellular pathways that contribute to oncogenesis. Here, we have defined a new role for PRMT5 in regulating and coordinating the interplay between the innate and adaptive immune response. This occurs, in part, through the influence of PRMT5 and E2F1 on RNA splicing and the presence of retained introns (RIs). We found that RIs have a propensity to form double-stranded RNAs that contribute to the innate response. Furthermore, many RIs contain non-canonical open-reading frames (ncORFs), which can be translated and then processed into small peptides that assemble with the MHC class I complex. Significantly, RI-derived peptides are highly immunogenic and, as a murine cancer vaccine, carrying a string of antigenic RI peptides, delayed tumour growth and enhanced survival. RIs are present in human tumour cells, and we identified T lymphocytes in human cancer patients, with antigen specificity for RI-derived peptides, that killed human tumour cells in vitro. Regulating intron retention thus offers a new therapeutic approach to enhance tumour immunogenicity.
- 17 August 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (9) , 3677-3703
Open AccessPRMT5-mediated intron retention triggers innate and adaptive immunity against cancer
PRMT5 is expressed at high levels in many cancers, where it regulates diverse cellular pathways that contribute to oncogenesis. Here, we have defined a new role for PRMT5 in regulating and coordinating the interplay between the innate and adaptive immune response. This occurs, in part, through the influence of PRMT5 and E2F1 on RNA splicing and the presence of retained introns (RIs). We found that RIs have a propensity to form double-stranded RNAs that contribute to the innate response. Furthermore, many RIs contain non-canonical open-reading frames (ncORFs), which can be translated and then processed into small peptides that assemble with the MHC class I complex. Significantly, RI-derived peptides are highly immunogenic and, as a murine cancer vaccine, carrying a string of antigenic RI peptides, delayed tumour growth and enhanced survival. RIs are present in human tumour cells, and we identified T lymphocytes in human cancer patients, with antigen specificity for RI-derived peptides, that killed human tumour cells in vitro. Regulating intron retention thus offers a new therapeutic approach to enhance tumour immunogenicity.